New Cardiovascular Disease Published Studies
Two new peer-reviewed research papers on cardiovascular disease have been published using GlycoCheck.
Cardiovascular Disease study: a 6-Year Follow-up
Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6-Year Follow-up Study, published in the Journal of Cardiovascular Translational Research, concluded that glycocalyx damage predicts a 5-fold increase in myocardial infarction, stroke, and cardiovascular related death (MACE) in a 6-year follow study on subjects without overt cardiovascular disease. Read the study here.
Cardiovascular Disease in Women study
Association of Gestational Diabetes with Subclinical Cardiovascular Disease on Echocardiogram and Endothelial Function Testing, published in Circulation (American Heart Association) concluded that Women with Gestational Diabetes Mellitus (GDM) were more likely to have increased LV wall thickness, adverse diastology and endothelial dysfunction nearly a decade postpartum. Adjusting for traditional cardiovascular risk factors attenuated some but not all parameters. These findings suggest that subclinical structural and functional cardiac and vascular changes may be a mechanism by which GDM causes increased risk of CVD.Read the study here.
Dr. Hans Vink, the inventor and co-founder of GlycoCheck and one of the world’s leading researchers of endothelial glycocalyx health, said “These papers confirm that for patients who have a damaged glycocalyx there is a correlation between microvascular health and cardiovascular health due to reduced capillary density.”
“GlycoCheck continues to play a role in important studies,” said Robert M. Long, co-founder of GlycoCheck and CEO of Microvascular Health Solutions. “As GlycoCheck continues to identify how cardiovascular diseases begins, healthcare practitioners have the opportunity to help patients with therapies like Endocalyx Pro that other studies show can restore glycocalyx health.
Improving Microvascular Health
Both Dr. Vink and Mr. Long are the co-creators of Endocalyx Pro™. Endocalyx Pro restores and maintains the endothelial glycocalyx lining inside the capillaries and improves capillary density and function.*
Endocalyx Pro is quickly gaining recognition as the tested product clinically shown to restore, regenerate, and protect the endothelial glycocalyx. The number of healthcare practitioners who now recommend Endocalyx Pro in their clinics is quickly growing.
Healthcare practitioners who are interested in offering Endocalyx Pro to their patients can complete the contact form at Microvascular.com to receive information about pricing and delivery.
*These statements have not been evaluated by the Food and Drug Administration. Tis product is not intended to diagnose, treat, cure or prevent any disease Using GlycoCheck.